QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:EGRX

Eagle Pharmaceuticals - EGRX Stock Forecast, Price & News

$36.86
-6.23 (-14.46%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$36.17
$43.59
50-Day Range
$36.86
$47.40
52-Week Range
$36.17
$58.25
Volume
218,906 shs
Average Volume
129,274 shs
Market Capitalization
$469.56 million
P/E Ratio
13.31
Dividend Yield
N/A
Price Target
$51.00

Eagle Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
38.4% Upside
$51.00 Price Target
Short Interest
Bearish
9.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
0.67mentions of Eagle Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-67.43%
From $7.86 to $2.56 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

841st out of 1,098 stocks

Pharmaceutical Preparations Industry

411th out of 536 stocks

EGRX stock logo

About Eagle Pharmaceuticals (NASDAQ:EGRX) Stock

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Eagle Pharmaceuticals Stock Down 1.3 %

Shares of EGRX Stock traded down $0.55 on Tuesday, hitting $42.54. The stock had a trading volume of 217 shares, compared to its average volume of 111,475. The company has a market cap of $541.96 million, a PE ratio of 15.56 and a beta of 0.61. The business has a 50 day moving average price of $43.69 and a 200 day moving average price of $46.05. Eagle Pharmaceuticals has a one year low of $38.50 and a one year high of $58.25.

Eagle Pharmaceuticals (NASDAQ:EGRX - Get Rating) last issued its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported $3.41 earnings per share for the quarter, topping analysts' consensus estimates of $3.19 by $0.22. The business had revenue of $115.87 million for the quarter, compared to analyst estimates of $122.39 million. Eagle Pharmaceuticals had a return on equity of 18.56% and a net margin of 14.56%. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Equities research analysts expect that Eagle Pharmaceuticals will post 7.86 EPS for the current year.

Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EGRX Stock News Headlines

Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Down 3.4%
Eagle Pharmaceuticals: Q4 Earnings Insights
See More Headlines
Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EGRX Company Calendar

Last Earnings
11/09/2021
Today
8/09/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.00
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$51.00
Forecasted Upside/Downside
+38.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
1 Analysts

Profitability

Net Income
$-8,630,000.00
Pretax Margin
21.03%

Debt

Sales & Book Value

Annual Sales
$171.55 million
Book Value
$13.66 per share

Miscellaneous

Free Float
9,147,000
Market Cap
$469.56 million
Optionable
Optionable
Beta
0.61

Key Executives

  • Mr. Scott L. Tarriff (Age 62)
    Founder, Pres, CEO & Director
    Comp: $2.18M
  • Mr. Brian Joseph Cahill (Age 53)
    Chief Financial Officer
    Comp: $783.96k
  • Mr. Ryan Debski
    Exec. VP, Gen. Counsel & Chief Compliance Officer
  • Mr. Daniel O'Connor (Age 42)
    Exec. VP, Chief Strategy Officer & Head of Corp. Devel.
  • Mr. John Kimmet
    Exec. VP of Marketing Oncology & Acute Care
  • Dr. Valentin R. Curt M.D.
    Sr. VP of Clinical Drug Devel.
  • Dr. Gaozhong Zhu Ph.D.
    Sr. VP of Pharmaceutical Devel.
  • Ms. Debra M. Hussain
    Sr. VP & Head of Commercial
  • Mr. Reiner Nowak
    Exec.













EGRX Stock - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EGRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EGRX, but not buy additional shares or sell existing shares.
View EGRX analyst ratings
or view top-rated stocks.

What is Eagle Pharmaceuticals' stock price forecast for 2022?

1 equities research analysts have issued 1 year price targets for Eagle Pharmaceuticals' shares. Their EGRX share price forecasts range from $51.00 to $51.00. On average, they predict the company's share price to reach $51.00 in the next year. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for EGRX
or view top-rated stocks among Wall Street analysts.

How has Eagle Pharmaceuticals' stock performed in 2022?

Eagle Pharmaceuticals' stock was trading at $50.92 on January 1st, 2022. Since then, EGRX stock has decreased by 23.7% and is now trading at $38.84.
View the best growth stocks for 2022 here
.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our EGRX earnings forecast
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to the consensus estimate of $46.70 million. Eagle Pharmaceuticals had a net margin of 14.56% and a trailing twelve-month return on equity of 18.56%. During the same quarter in the prior year, the firm posted $0.51 earnings per share.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Smith Graham & Co. Investment Advisors LP (1.82%), Allspring Global Investments Holdings LLC (1.63%), Scout Investments Inc. (1.15%), Assenagon Asset Management S.A. (0.65%), Los Angeles Capital Management LLC (0.27%) and Exchange Traded Concepts LLC (0.24%).
View institutional ownership trends
.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $38.84.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals (NASDAQ:EGRX) has a market capitalization of $494.82 million and generates $171.55 million in revenue each year. The specialty pharmaceutical company earns $-8,630,000.00 in net income (profit) each year or $2.77 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 102 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The official website for the company is www.eagleus.com. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at investors@eagleus.com.

This page (NASDAQ:EGRX) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.